Pathophysiology and therapy of irinotecan (CPT-11) induced delayed onset diarrhea (DD): A prospective assessment

被引：0
|
作者：
Misset, JL
Saliba, F
Giacchetti, S
Brain, E
Vassal, G
Bonnay, M
Bastian, G
Cote, C
Mahjoubi, M
Herait, P
Hagipantelli, R
Cvitkovic, E
机构：
[1] HOP PAUL BROUSSE,VILLEJUIF,FRANCE
[2] IGR,VILLEJUIF,FRANCE
[3] SOMPS,PARIS,FRANCE
来源：
EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：742 / 742
页数：1
相关论文
共 50 条
  • [21] Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective
    Bleiberg, H
    Cvitkovic, E
    EUROPEAN JOURNAL OF CANCER, 1996, 32A : S18 - S23
  • [22] Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion
    Kurita, A
    Kado, S
    Kaneda, N
    Onoue, M
    Hashimoto, S
    Yokoura, T
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (05) : 349 - 360
  • [23] Combination therapy with S-1 and irinotecan (CPT-11) for advanced or recurrent gastric cancer
    Takiuchi, Hiroya
    GASTRIC CANCER, 2009, 12 : 55 - 59
  • [24] Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma (NPC).
    Poon, D
    Chowbay, B
    Leong, SS
    Cheung, YB
    Toh, CK
    Tay, MH
    Lim, WT
    Tan, EH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 507S - 507S
  • [25] Combination therapy with S-1 and irinotecan (CPT-11) for advanced or recurrent gastric cancer
    Hiroya Takiuchi
    Gastric Cancer, 2009, 12 : 55 - 59
  • [26] RELATIONSHIP OF CPT-11 INDUCED DIARRHEA TO GLUCURONIDATION OF ITS METABOLITE SN-38
    GUPTA, E
    LESTINGI, TM
    MICK, R
    RAMIREZ, J
    VOKES, EE
    RATAIN, MJ
    CLINICAL RESEARCH, 1994, 42 (03): : A394 - A394
  • [27] IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA
    ABIGERGES, D
    ARMAND, JP
    CHABOT, GG
    DACOSTA, L
    FADEL, E
    COTE, C
    HERAIT, P
    GANDIA, D
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (06) : 446 - 449
  • [28] Irinotecan (CPT-11) in advanced colorectal cancer patients with progression after therapy with 5-FU.
    Mendez, M
    Salud, A
    García, C
    Navalón, M
    España, P
    Cruz, JJ
    Diz, P
    del Val, G
    del Prado, M
    ANNALS OF ONCOLOGY, 2000, 11 : 56 - 56
  • [29] EICOSANOID MEDIATED CL- SECRETION INDUCED BY THE ANTITUMOR DRUG, IRINOTECAN (CPT-11), IN THE RAT COLON
    SAKAI, H
    DIENER, M
    GARTMANN, V
    TAKEGUCHI, N
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1995, 351 (03) : 309 - 314
  • [30] Irinotecan (CPT-11) induced colitis: report of a case and review of Food and Drug Administration MEDWATCH reporting
    Sears, S
    McNally, P
    Bachinski, MSZ
    Avery, R
    GASTROINTESTINAL ENDOSCOPY, 1999, 50 (06) : 841 - 844
12345